S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
Log in

NASDAQ:PCVXLegend Biotech Stock Price, Forecast & News

$35.31
+1.32 (+3.88 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$33.21
Now: $35.31
$36.50
50-Day Range
$26.50
MA: $31.26
$35.45
52-Week Range
$17.80
Now: $35.31
$36.50
Volume152,773 shs
Average Volume148,497 shs
Market Capitalization$1.71 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Vaxcyte, Inc. a biopharmaceutical company, develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate, and complex antigen-based vaccines. The company has a license to Sutro Biopharma's Xpress CF platforms for cell free protein synthesis and site-specific conjugation. Vaxcyte, Inc. was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May, 2020. The company was incorporated in 2013 and is based in Foster City, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.7 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:PCVX
CUSIPN/A
CIKN/A
Phone650-837-0111

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees43
Market Cap$1.71 billion
Next Earnings DateN/A
OptionableNot Optionable
$35.31
+1.32 (+3.88 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PCVX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Legend Biotech (NASDAQ:PCVX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Legend Biotech?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Legend Biotech
.

What price target have analysts set for PCVX?

5 Wall Street analysts have issued 12 month price targets for Legend Biotech's shares. Their forecasts range from $37.00 to $55.00. On average, they anticipate Legend Biotech's stock price to reach $42.25 in the next year. This suggests a possible upside of 19.7% from the stock's current price.
View analysts' price targets for Legend Biotech
.

Has Legend Biotech been receiving favorable news coverage?

News headlines about PCVX stock have been trending somewhat negative this week, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Legend Biotech earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Legend Biotech
.

Who are some of Legend Biotech's key competitors?

Who are Legend Biotech's key executives?

Legend Biotech's management team includes the following people:
  • Mr. Grant E. Pickering, Co-Founder, CEO, Pres & Director (Age 52)
  • Dr. Ashish Khanna, Co-Founder and Chief Bus. Officer
  • Dr. Jeff Fairman, Co-Founder & VP of Research (Age 56)
  • Mr. Andrew L. Guggenhime M.B.A., CFO & Chief Bus. Officer (Age 52)
  • Mr. James Wassil M.B.A., M.S., Chief Operating Officer (Age 50)

When did Legend Biotech IPO?

(PCVX) raised $210 million in an IPO on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers.

What is Legend Biotech's stock symbol?

Legend Biotech trades on the NASDAQ under the ticker symbol "PCVX."

When did Legend Biotech's quiet period expire?

Legend Biotech's quiet period expired on Wednesday, July 22nd. Legend Biotech had issued 15,625,000 shares in its IPO on June 12th. The total size of the offering was $250,000,000 based on an initial share price of $16.00. During Legend Biotech's quiet period, underwriters and any insiders that worked on the IPO were restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Legend Biotech?

Shares of PCVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Legend Biotech's stock price today?

One share of PCVX stock can currently be purchased for approximately $35.31.

How big of a company is Legend Biotech?

Legend Biotech has a market capitalization of $1.71 billion. Legend Biotech employs 43 workers across the globe.

What is Legend Biotech's official website?

The official website for Legend Biotech is www.vaxcyte.com.

How can I contact Legend Biotech?

Legend Biotech's mailing address is 353 HATCH DR, FOSTER CITY CA, 94404. The company can be reached via phone at 650-837-0111.

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.